 The efficacy of the epidermal growth factor receptor EGFR inhibitors have been demonstrated in patients with non-small cell lung cancer NSCLC, pancreatic cancer PC and colorectal cancer CRC. Dermatological reactions can cause significant physical and psycho-social discomfort to patients. In the present study, the investigators evaluated the effect of epidermal growth factor EGF ointment on EGFR inhibitor-related skin side effects ERSEs. 